Approach to pulmonary hypertension.

被引:0
|
作者
Yung G.L. [1 ]
Rubin L.J. [1 ]
机构
[1] Division of Pulmonary and Critical Care Medicine, University of California, San Diego School of Medicine, La Jolla, CA
关键词
Pulmonary Hypertension; Idiopathic Pulmonary Fibrosis; Epoprostenol; Primary Pulmonary Hypertension; Pulmonary Hypertensive Patient;
D O I
10.1007/s11926-000-0030-x
中图分类号
学科分类号
摘要
Until recently, many physicians considered pulmonary hypertension a rare and esoteric condition that is difficult to diagnose and nearly impossible to treat. However, pulmonary hypertension can complicate a variety of relatively common diseases and, with the development of new and effective therapies, there is a need for greater awareness of this condition. Pulmonary hypertension should be considered when patients present with unexplained shortness of breath, chest pain, or syncope. The usual delay of 1 to 2 years between onset of symptoms and diagnosis underscores the importance of considering pulmonary hypertension in the differential diagnosis of patients who present with atypical cardiorespiratory symptoms.
引用
收藏
页码:517 / 523
页数:6
相关论文
共 50 条
  • [31] Primary pulmonary hypertension. A familial form.
    Scherpereel, A
    Steenhouwer, F
    Quandalle, P
    Dennetiere, S
    Haftel, Y
    Declercq, N
    Demarcq, JM
    REVUE DES MALADIES RESPIRATOIRES, 1997, 14 (05) : 409 - 412
  • [32] Genotype to Phenotype Analysis in Pulmonary Arterial Hypertension.
    Palazzini, M.
    Negro, L.
    Marinelli, A.
    Leci, E.
    Conficoni, E.
    Manes, A.
    Branzi, A.
    Galie', N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [33] Dichloroacetate reverses chronic hypoxic pulmonary hypertension.
    McMurtry, MS
    Archer, SL
    Lopaschuk, GD
    Hopkins, T
    Michelakis, ED
    CIRCULATION, 2000, 102 (18) : 100 - 100
  • [34] Thrombopoietin levels in the pulmonary vessels in patients with and without pulmonary hypertension.
    Haznedaroglu, IC
    Atalar, E
    Kocoglu, MH
    Aksu, S
    Goker, H
    Buyukasik, Y
    Sayinalp, N
    Ozcebe, OI
    Ozmen, F
    Dundar, SV
    Kirazli, S
    BLOOD, 2002, 100 (11) : 170B - 171B
  • [35] A Symposium on Essential Hypertension. An Epidemiological Approach
    Atwater, Reginald M.
    AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1952, 42 (07): : 868 - 869
  • [36] Resistant Hypertension. What Is the Best Approach?
    Barrios, Vivencio
    Escobar, Carlos
    REVISTA ESPANOLA DE CARDIOLOGIA, 2009, 62 (06): : 711 - 712
  • [37] Endovascular Device to Improve Pulmonary Arterial Compliance in Pulmonary Arterial Hypertension.
    Vollmers, Karl
    Scandurra, John
    Gainor, John
    Harder, Lucas
    Weir, Ken
    Pritzker, Marc
    Lang, Irene
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (13) : B69 - B69
  • [38] Effects of Trimetazidine on Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension.
    Chung, J. H.
    Choi, J. E.
    Cho, D. K.
    Oh, S. J.
    Yoon, S. J.
    Han, C. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [39] Invasive measurement of pulmonary arteriolar capacitance predicts survival in pulmonary hypertension.
    Mahapatra, S
    Sorajja, P
    Talreja, D
    McGoon, M
    Nishimura, R
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (6A): : 118E - 118E
  • [40] Right ventricular-pulmonary arterial coupling in experimental pulmonary hypertension.
    Wauthy, P
    Vassalli, F
    McEntee, K
    Naeije, R
    Brimioulle, S
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A167 - A167